Obsessive–compulsive disorder

Global Psychiatry Partnering Deal Trends, Players and Financials Directory/Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 29, 2022
Mental Health, Health, Tourette syndrome, Anxiety disorder, Learning disability, A-Z, Contract, Bulimia nervosa, Panic disorder, Obsessive–compulsive disorder, Hyperlink, Chapter Six, Chapter Two, Research, SEC, Directory, Chapter One, Narcolepsy, Chapter Four, Vascular dementia, Attention deficit hyperactivity disorder, Sleep apnea, Personality disorder, Cognitive deficit, Bipolar disorder, Technology, Review, Eating disorder, Alzheimer's disease, Chronic fatigue syndrome, Chapter Three, Tardive dyskinesia, Chapter Five, Sleep disorder, Body, Pharmaceutical industry, Petroleum, Insomnia, Dementia, Autism, Akathisia, Schizophrenia, Dystonia, Psychiatry, Delirium, Anorexia nervosa, Depression

The "Global Psychiatry Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Psychiatry Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Psychiatry Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 800 psychiatry deals.
  • The report takes readers through the comprehensive Psychiatry disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Psychiatry deals.
  • Global Psychiatry Partnering 2015 to 2022 includes:
    In Global Psychiatry Partnering 2015 to 2022, available deals and contracts are listed by:

BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto GBA Providing Coverage of Deep TMS™ for the Treatment of OCD

Retrieved on: 
Monday, January 31, 2022
Awareness, Obsessive–compulsive disorder, MAC, Private Securities Litigation Reform Act, Obsessions, Legislation, Patient, Macs, Insurance, U.S. Securities and Exchange Commission, Food, NASDAQ, Failure, Policy, National, LCD, Lists of diseases, Uncertainty, TASE, Technology, Psychiatry, Regulation of tobacco by the U.S. Food and Drug Administration, COVID-19, Deep, WHO, Annual report, Genta (company), Tic disorder, Company, Compulsions, World Health Organization, Health, GLOBE, Clinical, News, Knowledge, World, Achievement, Transcranial magnetic stimulation, Addiction, FDA, Quality of life, TMS, OCD, Review, Brainsway, Income, Health insurance, Pharmaceutical industry, Medicare, Palmetto

This final LCD is supported by the large body of compelling clinical evidence demonstrating the meaningful benefits derived by OCD patients from treatment with our innovative Deep TMS technology.

Key Points: 
  • This final LCD is supported by the large body of compelling clinical evidence demonstrating the meaningful benefits derived by OCD patients from treatment with our innovative Deep TMS technology.
  • We continue to work diligently to secure further coverage policy decisions from additional payors, and believe that, over time, other MACs will issue draft policies for Deep TMS coverage of OCD.
  • The patient selection criteria included in Palmettos final LCD is closely aligned with the Clinical TMS Societys recommended OCD coverage policy.
  • The U.S. Food and Drug Administration (FDA) granted BrainsWay De Novo clearance in August 2018 for Deep TMS as an adjunct form of therapy for patients suffering from OCD.

Global Deep Brain Stimulation Devices Market (2021 to 2026) - Featuring Boston Scientific, Fisher Wallace and LivaNova Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 18, 2022
Biotechnology, Health, Medical Devices, Delayed-maturation theory of obsessive-compulsive disorder, CAGR, Application, Dystonia, Parkinson's disease, Obsessive–compulsive disorder, Essential tremor, Allergy, Population, Ageing, Growth, Parkinson, Forecast, Chronic pain, Electrode, Deep brain stimulation, Skin, DBS, Depression, Rechargeable battery, Tic disorder, OCD, Lists of diseases, Prevalence, Brain, Alzheimer's disease, Pharmaceutical industry, Medical device, Epilepsy

Global deep brain stimulation (DBS) devices market is expected to undergo substantial growth during the forecast period owing to increasing prevalence of neurological disorders around the world.

Key Points: 
  • Global deep brain stimulation (DBS) devices market is expected to undergo substantial growth during the forecast period owing to increasing prevalence of neurological disorders around the world.
  • With increasing investment on R&D activities in neurological sector, the global deep brain stimulation (DBS) devices market is anticipated to grow further in the coming years.
  • Deep brain stimulation devices are based on therapy which involves implantation of electrodes within certain areas of the brain.
  • Global deep brain stimulation (DBS) devices market can be segmented based on product type, type, application, end user and region.

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Retrieved on: 
Wednesday, January 12, 2022
Income, U.S. Securities and Exchange Commission, Research, Patient, Tic disorder, Technology, News, Legislation, International Classification of Functioning, Disability and Health, Journal, Psychiatry, CBT, Private Securities Litigation Reform Act, COVID-19, Safety, Obsessive–compulsive disorder, Knowledge, NASDAQ, Â, GLOBE, World, Review, Health, Insurance, Brain stimulation, Market access, TMS, Uncertainty, Lists of diseases, Addiction, Obsessions, Journal of Psychiatric Research, Company, Compulsions, Quality of life, TASE, WHO, MD, Deep, World Health Organization, Annual report, OCD, Transcranial magnetic stimulation, FDA, Genta (company), Failure, Brainsway, Awareness, Pharmaceutical industry, Medicare

While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability.

Key Points: 
  • While prior research has demonstrated the safety and efficacy of Deep TMS in treating OCD, a recent study published in Brain Stimulation now shows the durability of Deep TMS and the significant reduction in functional disability.
  • Additionally, positive data published in the Journal of Psychiatric Research support the cost-effectiveness of Deep TMS relative to other available treatment options for OCD.
  • Durability was defined as the elapsed time from the end of the Deep TMS treatment course until there was a change in ongoing treatment.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

GrayMatters Health Closes $10M Round A Funding and Partnership in Japan

Retrieved on: 
Tuesday, January 11, 2022
Biomarker, Tel Aviv Sourasky Medical Center, PTSD, Patient, Technology, OMD, Tel Aviv University, LinkedIn, Lists of diseases, Harvard Medical School, Borderline personality disorder, Magnetic resonance, MDD, Safety, CEO, Obsessive–compulsive disorder, Mass, McLean Hospital, EFP, Mental disorder, GMH, Therapy, Neuroscience, Twitter, Brain, Mass General Brigham, GrayMatter Software, Anxiety disorder, Attention deficit hyperactivity disorder, Anhedonia, Magnetic resonance imaging, Machine learning, Medical imaging, Pharmaceutical industry, Prism

In addition to its investment, OMD obtained certain rights with regard to Prism in Japan and other countries in Asia.

Key Points: 
  • In addition to its investment, OMD obtained certain rights with regard to Prism in Japan and other countries in Asia.
  • Existing GMH investors, Marius Nacht and Joyance Ventures, also participated in the round.
  • "This funding round will help GrayMatters Health complete its clinical investigation, obtain clearance from regulatory authorities, and launch Prism for PTSD in the United States.
  • GMH was represented during the funding round by attorneys Yael Baratz and Inbal Perlstein-Mandelbaum, Senior Partners at Pearl Cohen Law Office.

Duchenne Muscular Dystrophy (DMD) Epidemiology Forecast to 2030 for the US, Germany, Spain, Italy, France, UK and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, December 17, 2021
Genetics, Pharmaceutical, Health, Autism spectrum, DMD, Population, Prevalence, Duchenne muscular dystrophy, Cardiomyopathy, Scoliosis, Epidemiology, OCD, ADHD, Patient, Disease, Profile, Attention deficit hyperactivity disorder, Mutation, ASD, Obsessive–compulsive disorder, Dentistry, Silviculture, Animal

This section provides glimpse of the Duchenne Muscular Dystrophy (DMD) epidemiology in the 7MM.

Key Points: 
  • This section provides glimpse of the Duchenne Muscular Dystrophy (DMD) epidemiology in the 7MM.
  • The total prevalent population of Duchene muscular dystrophy (DMD) in the 7MM was found to be 30,688 in 2020.
  • What is the historical Duchenne Muscular Dystrophy (DMD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Duchenne Muscular Dystrophy (DMD) during the forecast period (2021-2030)?

Pop Singer-Songwriter Taylor Castro's "Jade" Hits 4M Views Two Weeks After Release

Retrieved on: 
Monday, November 22, 2021
Fear, Abyss, Obsessive–compulsive disorder, Adolescence, Hollywood Music in Media Awards, DSPS, Latin Grammy Award for Best Pop Vocal Album, Human, Multimedia, Girl, Pink, Female, Jade, Music, Jewellery

The 22-year-old singer and actor reveals the new harmonica and piano-centered track as the "most personal song I've ever released."

Key Points: 
  • The 22-year-old singer and actor reveals the new harmonica and piano-centered track as the "most personal song I've ever released."
  • Produced by Peter Wallace (Pink, Michael Bolton), "Jade" elegantly tells the story of childhood friendship that fades away.
  • "After seven years of trying different sounds, I finally feel like I've found mine.
  • It's then only fitting that the story and lyrics behind 'Jade' would be the most personal and genuine I've ever released too.

2021 Global Duchenne Muscular Dystrophy Landscape: Notable Providers Include Sarepta Therapeutics, Nippin Shinyaku and Pfizer - ResearchAndMarkets.com

Retrieved on: 
Friday, October 29, 2021
Pharmaceutical, Health, Other Health, Mutation, Epidemiology, Patient, DMD, Obsessive–compulsive disorder, Scoliosis, Profile, Attention deficit hyperactivity disorder, OCD, Duchenne muscular dystrophy, Population, Customer insight, Prevalence, ADHD, Dentistry, Renewable energy

This 'Duchenne Muscular Dystrophy (DMD) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Duchenne Muscular Dystrophy (DMD), historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy (DMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Key Points: 
  • This 'Duchenne Muscular Dystrophy (DMD) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Duchenne Muscular Dystrophy (DMD), historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy (DMD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Duchenne Muscular Dystrophy (DMD) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Duchenne Muscular Dystrophy (DMD) market size from 2018 to 2030.
  • Organize sales and marketing efforts by identifying the best opportunities for Duchenne Muscular Dystrophy (DMD) market.
  • To understand the future market competition in the Duchenne Muscular Dystrophy (DMD) market.

OCD Awareness Week: We Need New Solutions, More Conversations

Retrieved on: 
Wednesday, October 13, 2021
Goodman, Solution, Multi-monitor, Awareness, LinkedIn, List of minor secular observances, Health, Compulsions, OCD, Population, Gold, Patient, Obsessions, Yale–Brown Obsessive Compulsive Scale, McIngvale, Baylor College of Medicine, Obsessive–compulsive disorder, Suicide, YBOCS, Baylor University, Medical device

OCD Awareness Week 2021 takes place October 1016.

Key Points: 
  • OCD Awareness Week 2021 takes place October 1016.
  • If you don't treat OCD effectively, this condition persists and often gets worse.
  • In addition to using the most current assessment solutions, Dr. Storch encourages those providing services to individuals with OCD to engage in meaningful discussions during OCD Awareness Week.
  • Storch and Young on the importance of OCD awareness, read the nView blog post " OCD Awareness Week: We Need New Solutions, More Conversations ."

Global Obsessive-Compulsive Disorder Clinical Trials Review 2021: Phase, Trial Status, End Points Status and Sponsor Type - ResearchAndMarkets.com

Retrieved on: 
Monday, October 11, 2021
Health, Mental Health, Clinical Trials, Disorder, Trial, Obsessive–compulsive disorder, E7 (countries), Clinical trial, Central nervous system, G7, E7, Decision-making, Pharmaceutical industry

The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Obsessive-Compulsive Disorder - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Obsessive-Compulsive Disorder - Global Clinical Trials Review, H2, 2021" provides an overview of Obsessive-Compulsive Disorder Clinical trials scenario
    This report provides top line data relating to the clinical trials on Obsessive-Compulsive Disorder .
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    the report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    the report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Obsessive-Compulsive Disorder to Central Nervous System Clinical Trials